PRESS-RELEASE filed Nov 20, 2026 at 12:58 ET
SRX Global issued a press release commenting on Pfizer's $330M upfront licensing deal with Starna for pre-IND CAR-T programs, noting it validates industry interest in engineered T-cell platforms but stating it is not a valuation benchmark for SRX's pending acquisition of CERo Therapeutics. SRX also provided an update on CER-1236's Phase 1/1b trial, reporting no dose-limiting toxicities in the second cohort and expansion of clinical trial sites. The release is primarily a strategic commentary and clinical update, with no new financial data or definitive clinical results.